Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Exploring the Complement System in Human Disease

M. Kathryn Liszewski and John P. Atkinson, MD  |  Issue: February 2010  |  February 1, 2010

The clinical, genetic, and immunopathologic understandings gained from studying aHUS illustrate how a powerful recognition and effector system, the AP, reacts to altered self. A response to acute injury must be appropriately balanced. Too much activation or too little regulation promotes undesirable tissue damage. More recently, mutations in these same complement regulatory proteins have been identified in preeclampsia, particularly the HELLP syndrome (hemolysis, elevated liver enzymes, low platelets).24,25 Further, patients with SLE and/or anticardiolipin antibody syndrome who developed preeclampsia had a greater frequency of those mutations.26

Figure 4: Atypical hemolytic uremic syndrome and deficiency of complement regulators.
click for large version
Figure 4: Atypical hemolytic uremic syndrome and deficiency of complement regulators. A: A normal number of complement regulators on endothelial cells (each MCP represents about 50,000 copies), efficiently inactivates C3bs that land on the cell surface (i.e., converts to iC3b). B: A deficiency (i.e., haploinsufficiency) with half normal amounts of MCP results in excessive C3b deposition. Also, downstream events of C5 activation occur,namely C5a liberation and membrane attack complex formation. This overly exuberant response to endothelial cell damage leads to a procoagulant state with microthrombi causing glomerular injury.

Chronic Debris Deposition Disease: The Example of AMD

In 2005, four research teams identified a strong genetic link between AMD and a polymorphism in the complement regulator FH.5–8 The lipid/pig­ment-rich waste known as drusen appears to be a site of an undesirable amount of AP activation (See Figure 5, below).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In 2001, Greg Hageman, PhD, and colleagues demonstrated the presence of C3 fragments, membrane attack complex terminal components, and FH in drusen.9 They proposed a model for AMD pathogenesis based on a prominent role of inflammation. Simply put, according to this model, drusen accumulate, AP is activated, and an excessive inflammatory response damages the retina. Chronic liberation of proinflammatory C3a and C5a anaphylatoxins in the retina are almost certainly deleterious, including their role as a trigger to initiate vascular endothelial growth factor invasion of chorodial vessels (wet AMD) into the macula.27

The polymorphism in FH associated with AMD changes a single amino acid in a region of the protein important for its binding to charged molecules (such as glycosaminoglycans) that are commonly found on cell surfaces and matrices.3 The prevalent hypothesis, for which there is considerable evidence, posits that FH carrying this change (tyrosine in the major allele to a histidine in the minor allele) binds less well to a drusen and therefore results in more AP activation for a given amount of debris. Of great interest, this single amino acid change appears to protect neonates and young children from serious streptococcal infections. Group A beta hemolytic streptococci bind to and coat themselves with FH for protection from complement attack.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:ConditionsEducation & TrainingResearch Rheum Tagged with:complementgeneticsImmunityinflammation

Related Articles

    2015 ACR/ARHP Annual Meeting: Next Generation Sequencing and Disease Mechanisms

    February 17, 2016

    SAN FRANCISCO—By harnessing the power of next generation sequencing strategies and combining them with clever statistical strategies and tools, investigators are striving to define causal pathways of and mechanisms underlying complex diseases, such as rheumatoid arthritis, according to Soumya Raychaudhuri, MD, PhD, associate professor, Harvard Medical School, Brigham and Women’s Hospital, Boston, during a session…

    2015 ACR/ARHP Annual Meeting: Cellular Triggers in Inflammatory Disease

    April 14, 2016

    SAN FRANCISCO—What factors help determine whether or not inflammation resolves, leading to healing, or becomes chronic, leading to disease and tissue destruction? A number of important cells, including toll-like receptors, mast cells, anti-citrullinated protein antibodies, complement and interferon, all play their own role in this process. By understanding how they act in innate and adaptive…

    Case Report: Refractory Calciphylaxis in Lupus

    May 17, 2018

    Calciphylaxis is a poorly understood and life-threatening ischemic vasculopathy characterized by calcification of the small- and medium-size arteries in the skin, subcutaneous tissue and internal organs, which leads to thrombosis, tissue necrosis and painful skin ulcerations that won’t heal. The disease has a 50–80% mortality rate. Although affected patients typically have end-stage renal disease (ESRD)…

    Translating Genetic Discoveries into Rheumatic Therapies

    March 18, 2018

    SAN DIEGO—Will rheumatologists soon be able to use data from genetics and genome-wide association studies to more accurately predict disease and develop new therapies for rheumatic diseases? At a Nov. 5 session at the 2017 ACR/ARHP Annual Meeting, experts shared their views on how to glean this useful knowledge from genomics studies. The cost to develop…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences